SCHEMBL4021235

SCHEMBL4021235

CCCCCCCCCCCCNS(=O)(=O)c1ccc(CN(OC(=O)C=O)C2CCCC2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
HTT P42858 2/20 0.45
TSHR P16473 1/20 0.45
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 2/20 0.35
LMNA P02545 2/20 0.34
EPHX2 P34913 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
RECQL P46063 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
TBXA2R P21731 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044430 0.82 KMT2A (0.52) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL4021233 0.81 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1855668 0.80 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1851100 0.79 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1854872 0.73 KMT2A (0.55) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1856185 0.72 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL4715407 0.71 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1851101 0.71 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL6719223 0.70 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMEN1HTTTSHR
SCHEMBL1853154 0.69 KMT2A (0.66) SMN1; SMN2KMT2AMEN1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 SMN1; SMN2 2147/4885KMT2A 2981/4885MEN1 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.